Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D₁/D₅ Receptors

Abstract

Tavapadon is a potent, selective G protein-biased partial agonist for the dopamine D₁/D₅ receptors, with positive experimental results in phase 3 trials for the treatment of Parkinson's disease (PD). This study aims to study the structure–activity relationship (SAR) of tavapadon to discover novel compounds with improved binding activity to D₁/D₅ receptors. In this work, a series of tavapadon derivatives were designed and synthesized based on the pharmacophores of tavapadon. Their binding activity to D₁/D₅ receptors was evaluated by determining in vitro median effect concentration (EC₅₀). The binding mode was predicted by molecular docking. Our data showed that among those compounds, III-1 exhibited a similar binding pose to tavapadon at D₁ dopamine receptors and demonstrated nanomolar potency for both D₁ and D₅ receptors. Compound III-1 is a potent partial agonist for the D₁/D₅ receptors, and may be a potent alternative to tavapadon for the treatment of PD in further study.

Keywords

dopamine 1 receptor - dopamine 5 receptor - partial agonists - tavapadon - EC₅₀

• References

• 1 Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 2017; 16 (12) 829-842
• 2 Xing C, Zhuang Y, Xu TH. et al. Cryo-EM structure of the human cannabinoid receptor CB2-G_i signaling complex. Cell 2020; 180 (04) 645-654.e13
• 3 Zhuang Y, Xu P, Mao C. et al. Structural insights into the human D₁ and D₂ dopamine receptor signaling complexes. Cell 2021; 184 (04) 931-942.e18
• 4 Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors—IUPHAR Review 13. Br J Pharmacol 2015; 172 (01) 1-23
• 5 Abi-Dargham A, Mawlawi O, Lombardo I. et al. Prefrontal dopamine D₁ receptors and working memory in schizophrenia. J Neurosci 2002; 22 (09) 3708-3719
• 6 Beninger RJ, Miller R. Dopamine D₁-like receptors and reward-related incentive learning. Neurosci Biobehav Rev 1998; 22 (02) 335-345
• 7 Lemon N, Manahan-Vaughan D. Dopamine D₁/D₅ receptors gate the acquisition of novel information through hippocampal long-term potentiation and long-term depression. J Neurosci 2006; 26 (29) 7723-7729
• 8 McNab F, Varrone A, Farde L. et al. Changes in cortical dopamine D₁ receptor binding associated with cognitive training. Science 2009; 323 (5915): 800-802
• 9 Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D₁ receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007; 10 (03) 376-384
• 10 Albeely AM, Nolan CJ, Rasmussen DJ, Bailey CDC, Perreault ML. Cortical dopamine D₅ receptors regulate neuronal circuit oscillatory activity and memory in rats. CNS Neurosci Ther 2023; 29 (09) 2469-2480
• 11 Kawahata I, Finkelstein DI, Fukunaga K. Dopamine D₁–D₅ receptors in brain nuclei: implications for health and disease. Receptors (Basel) 2024; 3 (02) 155-181
• 12 Moraga-Amaro R, González H, Ugalde V. et al. Dopamine receptor D₅ deficiency results in a selective reduction of hippocampal NMDA receptor subunit NR2B expression and impaired memory. Neuropharmacology 2016; 103: 222-235
• 13 Castello J, Cortés M, Malave L. et al. The dopamine D₅ receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Sci Rep 2020; 10 (01) 2542
• 14 Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63 (01) 182-217
• 15 Hall A, Provins L, Valade A. Novel strategies to activate the dopamine D₁ receptor: recent advances in orthosteric agonism and positive allosteric modulation. J Med Chem 2019; 62 (01) 128-140
• 16 Brodney M, Davoren JE, Dounay AB, Efremov IV, Gray DLF. Heteroaromatic compounds and their use as dopamine D₁ ligands. U.S. Patent 10696658–B2. June, 2020
• 17 Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S. Rationale and development of tavapadon, a D₁/D₅-selective partial dopamine agonist for the treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 2024; 23 (04) 476-487
• 18 Abbvie News Center. Cerevel therapeutics announces positive topline results for tavapadon in phase 3 adjunctive trial for people living with Parkinson's disease (EB/OL). Accessed April 18, 2024 at: https://news.abbvie.com/2024-04-18-Cerevel-Therapeutics-Announces-Positive-Topline-Results-for-Tavapadon-in-Phase-3-Adjunctive-Trial-for-People-Living-with-Parkinsons-Disease
• 19 Arias-Montaño JA, Floran B, Floran L, Aceves J, Young JM. Dopamine D(1) receptor facilitation of depolarization-induced release of gamma-amino-butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels. Synapse 2007; 61 (05) 310-319
• 20 Jones-Tabah J, Mohammad H, Paulus EG, Clarke PBS, Hébert TE. The signaling and pharmacology of the dopamine D₁ receptor. Front Cell Neurosci 2022; 15: 806618
• 21 Teng X, Chen S, Nie Y. et al. Ligand recognition and biased agonism of the D₁ dopamine receptor. Nat Commun 2022; 13 (01) 3186
• 22 Martini ML, Ray C, Yu X. et al. Designing functionally selective noncatechol dopamine D₁ receptor agonists with potent in vivo antiparkinsonian activity. ACS Chem Neurosci 2019; 10 (09) 4160-4182
• 23 Martini ML, Liu J, Ray C. et al. Defining structure-functional selectivity relationships (SFSR) for a class of non-catechol dopamine D₁ receptor agonists. J Med Chem 2019; 62 (07) 3753-3772
• 24 Davoren JE, Nason D, Coe J. et al. Discovery and lead optimization of atropisomer D₁ agonists with reduced desensitization. J Med Chem 2018; 61 (24) 11384-11397